Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
Evaluation of Pharmacokinetics, Safety, Efficacy and Immunogenicity of rAHF-PFM in Previously Treated Hemophilia A Patients - A Continuation Study
Sponsor: Baxalta now part of Shire
This PHASE2/PHASE3 trial investigates Hemophilia A and is currently completed. Baxalta now part of Shire leads this study, which shows 9 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Nov 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Nov 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .